MMP13 and non-small cell lung carcinoma: Among these, the 10 most significant genes (GSTT2B, HMGA2, AC135050.2, ANKRD33B, MMP13, PLA2G2D, RASGEF1A, BIRC7, DCAF4L2, and CHMP7) may serve as potential genomic biomarkers for predicting which patients with NSCLC are most likely to respond to PD-1 immunotherapy.